Oricon Pharmaceuticals Private Limited
About Oricon Pharmaceuticals Private Limited
Data last updated:
Oricon Pharmaceuticals Private Limited is a private limited company based in Rohtak, Haryana, India. It operates in the service-based operations segment of the business services sector. It was incorporated on 11 January 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Haryana, under CIN U74999HR2017PTC067029. Its GSTIN is 06AACCO4304N1ZG (Haryana).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Parvesh Kumar and Satya Pal Arora.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 43/8 A Shivaji Colony, Rohtak, Haryana, India – 124001.
As per the financials filed for FY 2024, the company reported a revenue of ₹2.28 Lakh, a decline of 61% compared to the previous year. For the same year it recorded a net loss of ₹3,256 (net margin -1.4%) and EBITDA of ₹70,556 (EBITDA margin 30.9%). Revenue has declined at a compounded annual rate (CAGR) of 37% over three years and 25% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Oricon Pharmaceuticals Private Limited's registered office is in Rohtak, Haryana. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address43/8 A Shivaji Colony, Rohtak, Haryana, India – 124001
- IndustryBusiness Services, Other Services, Miscellaneous Business Activities
To see the full contact details of Oricon Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Oricon Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Oricon Pharmaceuticals Private Limited, buy the company report.
Financials of Oricon Pharmaceuticals Private Limited
FY 2025 filings availableOricon Pharmaceuticals Private Limited reported revenue of ₹2.28 Lakh (down 61% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 25% over five years, including a 61% fall in the latest year. EBITDA rose 4% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹70,556 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹3,256 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 30.9% | ||||
| Net Profit Margin | -1.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Oricon Pharmaceuticals Private Limited, buy the company report.
Board of directors of Oricon Pharmaceuticals Private Limited
Oricon Pharmaceuticals has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Parvesh Kumar | Director | 11 Jan 2017 | 9 Years 9 Months | Current |
| Satya Pal Arora | Director | 28 Nov 2022 | 3 Years 11 Months | Current |
Peer comparison
Oricon Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cestrum Pharmaceuticals Private Limited | ₹2.33 Lakh (FY 2019) | Pune, Maharashtra, India | ||||
| Levisto Pharmaceuticals Private Limited | ₹2.29 Lakh (FY 2023) | Panchkula, Haryana, India | ||||
| Oricon Pharmaceuticals Private Limitedthis company | ₹2.28 Lakh (FY 2024) | -₹3,256 | -1.4% | -61.0% | Rohtak, Haryana, India | |
| Inpure Pharmaceuticals Private Limited | ₹2.27 Lakh (FY 2023) | 2170.0% | Delhi, India | |||
| Skymed Pharmaceuticals Private Limited | ₹2.27 Lakh (FY 2024) | -16.0% | New Delhi, Delhi, India |
To see the full peer comparison of Oricon Pharmaceuticals Private Limited, buy the company report.
Auditor
Oricon Pharmaceuticals Private Limited is audited by SURESH AJAY & CO for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SURESH AJAY & CO | FY 2017 | 091340 |
Shareholding
The shareholding of Oricon Pharmaceuticals Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Oricon Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Oricon Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Oricon Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Oricon Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AACCO4304N1ZG | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Oricon Pharmaceuticals Private Limited, buy the company report.
Recent activity
Oricon Pharmaceuticals Private Limited has 5 board changes on record since 2017: 2 appointments and 3 cessations. The latest: Komal Sharma ceased to be Director on 28 Nov 2022.
Frequently asked questions
Oricon Pharmaceuticals is an active private limited company based in Rohtak, Haryana, India. The company works in other services, within the business services industry. It was incorporated on 11 January 2017 (9+ years old) and is registered under CIN U74999HR2017PTC067029.
Oricon Pharmaceuticals has 2 current directors:
- Parvesh Kumar - Director
- Satya Pal Arora - Director
The latest financial statements of Oricon Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Oricon Pharmaceuticals is 06AACCO4304N1ZG, registered in Haryana.
The CIN (Corporate Identification Number) of Oricon Pharmaceuticals is U74999HR2017PTC067029. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Oricon Pharmaceuticals was incorporated on 11 January 2017, making it 9+ years old. It is registered with the Registrar of Companies, Haryana.
The peers of Oricon Pharmaceuticals by revenue are Cestrum Pharmaceuticals Private Limited, Levisto Pharmaceuticals Private Limited, Inpure Pharmaceuticals Private Limited, Skymed Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Komal Sharma ceased to be Director on 28 Nov 2022. Satya Pal Arora was appointed as Director on 28 Nov 2022. Raj Bala ceased to be Director on 01 Mar 2021. Oricon Pharmaceuticals has 5 board changes on record in total.
The registered office of Oricon Pharmaceuticals is at 438 A Shivaji Colony, Rohtak, Haryana, India – 124001.
Oricon Pharmaceuticals operates in the business services industry, in the other services segment.
The compliance status of Oricon Pharmaceuticals is compliant as of 24 July 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
